initi coverag
initi neutral may keep truckin cautiou base biz
invest summari initi coverag neutral rate
price target think pipelin may help amgen
keep truckin given credit mani program detail review
think investor start pay attent pipelin sourc
stock upsid especi oncolog base case model credit
develop oncolog base busi expect lower
street around neulasta enbrel aranesp report conduct
detail analysi around pipelin near-term readout bite migrain
convers head global develop
model signific eros neulasta aranesp due biosimilar
total revenu slightli vs first biosimilar neulasta
recent approv could see two biosimilar time end
estim neulasta lower vs consensu project
aranesp doesnt biosimilar think recent biosimilar epogen
launch put pressur amgen aranesp franchis think street
aranesp flat vs model revenu vs
pipelin front pay attent amgen bite program
whether emerg dark hors competitor cell therapi base
case model new pipelin revenu estim
unadjust basi think investor begin ponder
whether bi-specif platform compet vs cell therapi
get import updat decemb short-act bite aml
multipl myeloma focus multipl myeloma updat though amgen
sound posit think updat around longer half-
life version key determin commerci potenti model
bite expans base case unadjust sale
pipelin analysi program interest antibodi
tezepelumab mutein posit aimovig launch
cgrp get data antibodi migrain later year
patient proof-of-concept studi interest see
target drive migrain prevent vs cgrp sinc good scientif rational
target well also expect tri studi tezepelumab atop
dermat point reason initi would less
disclosur section may found page
initi coverag
think pipelin may help keep truckin bake good
amount detail review
amgen blockbust growth product sale
diversifi biopharmaceut compani special six therapeut area
includ cardiovascular diseas oncolog bone health neurosci nephrolog
inflamm compani also grow biosimilar franchis
think investor pay attent pipelin
particularli oncolog assign credit oncolog
expans base case note risk
base busi estim bit lower consensu
howev give ampl credit key pipelin program achiev
proof-of-concept upsid dcf lower biotech peer
review rel rate
event watch
bite platform take bite car-t
believ bi-specif place hematolog oncolog treatment
biosimilar erod neulasta busi faster expect
model eros street next year think onpro
help defend also think biosimilar take share
recent launch product biosimilar busi drive
stabil growth base busi biosimilar eros
think biosimilar could bring stabil busi confid
recent aimovig launch base check
relev eventn drugn data bcma multipl myeloma short-act think data aml think studi antibodi migrain prevent ye medic meet act bite datavarioushematology/oncologyposs cantor fitzgerald exhibit blockbust growth product salessourc cantor fitzgerald oper metric perform
valuat use probability-adjust dcf analysi valu share assum discount rate model revenu
assum termin valu roughli valuat base termin valu reflect compani
intern engin pipelin program yet model
compani report factset research cantor fitzgerald research price
inc amgn-u recent outstand cap valu day interest cover current market rate valu mm outfidel manag research vanguard group research manag co global fund fund manag manag invest capit manag stanley smith barney llc privat bank invest key comp estim vs consensu
rate rate share neutral price
exhibit annual estim vs revenu revenu cantor fitzgerald factsetexhibit quarterli estim vs revenu revenu cantor fitzgerald factsetexhibit comp compspricemarket cap ev sale ep price-to-earnings factset price diversifi biopharma compani key franchis
diversifi biopharma compani nearli top line quarterli cash dividend
therapeut area focu addit biosimilar franchis cardiovascular
question/concern pipelin off-set gener eros product like enbrel
think bite hem/onc tezepelumab inflamm neuro drive frontier growth
exhibit growth product pipelin salessourc cantor fitzgerald biosimilarrituxin biosimilarremicad biosimilarmvasi avastin tezepelumabamjevita humira aimovigrepathaexhibit sale therapeut categorysourc cantor fitzgerald researchcardiovascular health healthhematology/oncolog although growth slow legaci product think mani asset
still grow market pipelin
view product three bucket legaci growth frontier growth
year growth bucket grown significantli help off-set legaci eros
see interest pipelin opportun potenti ignor could
data next month
remind limit attent paid tezepelumab asthma data
exhibit busi -- legaci growth frontierlegaci product product erod next year growth product recent launch past year current frontier growth late stage pipelin approv enbrel antibodyaranesprepathalong half-lif bitessensiparaimovigbiosimilar franchisebiosimilar franchiseomecamtivparsabivsourc cantor fitzgerald research compani data reflect amgn past present futur new biosimilar threat horizon new
product like repatha aimovig even biosimilar could off-set
rel stabl stori focu product eros new product growth come year
past year creat signific valu bottom line cash return
oper effici improv
exhibit cantor reflect stand storywher come past month solid execut base busi delay biosimilar entrant margin oper goal success tax benefit share surpris posit pipelin asset tezepelumab major deal though investor clamor broad clinic develop immuno-oncolog repatha outcom data positivewher current await updat year end develop bite aimovig launch migrain manag turnov veteran commer biosimilar neulasta launch curiou whether tabl whether expect bolt-on compani mani partnership collabor go greater clariti compani plan oncolog aimovig repatha launch curv payer-sensit market remain like see eros neulasta interest see much onpro enbrel court case sandoz subsequ appeal impact enbrel tail biosimilar continu ramp ex-u humira launch curiou progress biosimilar eculizumabsourc cantor fitzgerald research thesi still posit believ keep truck see
less upsid biotech peer dcf analysi
launch neutral rate pt
think investor pay attent pipelin particularli oncolog
assign credit oncolog expans base case howev give ampl
credit key pipelin program achiev proof-of-concept
note risk neulasta epogen base busi
estim bit lower consensu
swing factor lot cash return deploy sharehold
upsid dcf lower biotech peer review rel rate
chang sinc prior coverag posit inclin pipelin
stock less upsid compar large-cap peer
share perform well vs nbi busi remain
stabl though still wait pipelin
see pipelin readout next month matter reflect credit
base case valuat report highlight bite readout oncolog decemb
updat
risk neulasta curvebal model decreas sale next
year end could three biosimilar
watch aranesp trend close sinc biosimilar epogen
overweight cover louis chen first epogen biosimilar approv
watch biosimilar epogen might affect brand long-act aranesp
risk deploy capit transform deal new manag
chang commerci
think key driver share next month pipelin progress quarterli
earn report cash deploy
biosimilar busi begin emerg top-lin contributor
think earn report watch close product like neulasta aimovig
neulasta competit biosimilar
aimovig migrain earli day launch teva neutral cover louis
chen migrain product approv septemb
amgevita biosimilar humira launch ex-u current ex-u sale
origin product
new pipelin opportun like bite expans drive share
exhibit catalyst drug franchis next month relev eventn drugn franchisereadoutstock importancecantor data bcma multipl myeloma short-act think moderateshort act bite help us think platform though focus posit longer act data aml think moderateshort act bite help us think platform though focus posit longer act studi antibodi migrain prevent ye medic meet think commer interesting- product could expand compani leadership migrainelonger-act bite datavarioushematology/oncologyposs think readout help us understand competit posit vs therapi like car-tsourc cantor fitzgerald research present what proprietari report detail concis discuss pipelin late-
early-stag program interest
think pipelin biggest factor could move valuat next month
recent discuss manag head clinic develop around
differ near-term pipelin catalyst includ bite tezepelumab
detail analysi preview bite platform data present dec
preview antibodi readout expect year-end fit migrain
updat thought tezepelumab program beyond asthma
discuss favorit earli stage program mutein find interest
investor debat view
debat high level view
amgen becom competitor hematolog oncolog car-t bi-specif
platform call bite current approv drug market blincyto
compani develop platform mani indic expect updat
decemb major medic meet american societi hematolog
new competit impact aimovig launch migrain
expect new player could potenti launch next month
check think unmet need high
think relat pipelin
get gener gist valuat look somewhat expens small-mid cap land
compani done mani collabor partnership
think risk base busi
new biosimilar hit market continu enbrel competit
howev compani launch new product expand current one like
larg cap univers lower revenu ep growth next year
though perhap less eros biosimilar aimovig could drive growth
consensu project top- bottom-lin compound-annual-growth-rate
project bit higher top- bottom-lin compound-annual-growth-rate
period compani still growth univers
exhibit rel revenu compound-annual-growth-rate larg cap biopharma stockssourc factset cantor rel ep compound-annual-growth-rate larg cap biopharma stockssourc factset cantor trade premium space ex
pe multipl vs biopharma averag
exhibit rel valaut larg cap biopharma stock pe multiplesourc factset cantor pe septemb
next year project fairli stabl revenu rel
recent futur new product launch help stabil revenu
abbvi humira sale ex-u launch biosimilar year
base busi product biggest eros includ neulasta epogen
biggest growth product aimovig biosimilar tezepelumab
exhibit amgen legaci growth product revenuessourc cantor fitzgerald revenu amgen revenuesnew amgen product revenu valuat use probability-adjust dcf analysi
month price target
amgen statementalethia young cantor tax ebit less valu valuetermin septemb
risk signific eros base busi launch challeng product innov
volatil concern around enbrel quarterli result
greater expect eros base busi challeng earn project
lower consensu revenu project next year
cautiou contribut new pipelin think estim
achiev
payer price challeng new current product
enbrel sale dynam area key focu investor
discuss enbrel net price decreas stock almost
mani new product brand launch market signific
competit like migrain inflamm cardiovascular
tezepelumab could signific opportun inflamm space
setback asthma program safeti signal remain risk expect
view bite platform oncolog potenti under-appreci opportun
compani possibl platform gener market product
legaci growth product
product focu
consid model next month earn amgen
focus enbrel neulasta repatha sensipar see dynam still
affect volum price
exhibit base busi consider next month productfranchiseconsiderationsour viewenbrelinflammationcontinu competit dermatologyw model continu eros note dermatolog repres revenu enbrelneulastaoncologyfirst biosimilar approv coheru cover could approv biosimilar consider onpro neulasta unit defens make neulasta revenuesw model growth eros neulasta market outcom studycompetit praluent posit outcom studyw still cautiou repatha model growth next year parsabivnephrologyw expect gener sensipar enter market parasbiv next gener launchingw model eros sensipar moder growth parsabiv sinc ultim predict gener may factor marketsourc cantor fitzgerald research neulasta biosimilar factor earn
could two neulasta biosimilar approv sever product also
neulasta experi eros start biosimilar
would expect eros pick time
sandoz cover also biosimilar neulasta develop
exhibit amgen base busi biosimilar competitionamgen productgener productexclus expirationu biosimilarseu biosimilarsenbreletanerceptlatest patent litig pendingerelzi fda approv pend litigationbenepali launcherelzi launchneupogenfilgrastimn/anivestym approvalzarxio sandoz approvalaccofilfilgrastim hexalgrastofilneulastapegfilgrastimn/afulphila estimate launchudeyca potenti approv chmp opinion udenyca late julyepogenepoetin alfan/aretacrit fda approvedabseamedbinocritepoetin alfa hexal hexal sourc cantor fitzgerald research compani data model lower revenu consensu neulasta account potenti biosimilar risk
estim significantli differ vs consensu expect see greater impact
think reason bit conserv potenti impact
neulasta biosimilar cover louis chen potenti coheru nr
onpro share may serv defens biosimilar
could also lower price maintain lion share market
exhibit neulasta ww sales- cantor vs consensussourc cantor fitzgerald total cantorconsensus- factset septemb
slightli enbrel vs consensu next year
enbrel sale mostli come rheumatolog point
estim sale dermatolog competit past
model price pressur volum loss
although intellectu properti right till late
concern sandoz nr challeng intellectu properti earlier
exhibit enbrel ww sales- cantor vs consensussourc cantor fitzgerald total sale cantorenbrel total sale consensu cautiou consensu repatha watch outcom data
ahead consensu repatha
repatha look variou consensu sourc seem like bit outlier
still overal bit lower consensu
think market continu grow gradual outcom label also
competit remain tough payer market view
exhibit repatha ww sales- cantor vs consensussourc cantor fitzgerald research repatha total cantorww repatha total consensu factset bullish aimovig launch think price reason outcom evid
quickli remain mani suffer migrain
slightli ahead consensu think launch could pick momentum
dont know exactli much pay novarti cog line aimovig
revenu know signific portion profit
model paid novarti sinc discov drug model royalti
cog line sinc book revenu also receiv one-tim
payment ex-u territori
exhibit aimovig ww sales- cantor vs consensussourc cantor fitzgerald research total cantoraimovig total consensu factset septemb
check broadli posit recent aimovig launch migrain
spoke doctor roughli prescrib migrain patient per month us
patient physician enthusiast use drug unmet need remain high
aimovig first-to-market posit highli advantag physician
put bolu refractori patient onto drug
think market sticki patient see effect doctor view subq
cgrp equival term efficaci dont think patient want stop drug
order switch
key risk patient switch patient access program lilli ow cover
louis chen teva abl facilit access drug easili quickli
risk lose share initi bolu
prescrib note payer access consider key driver cgrp market
check key factor watch close see cgrp market broadli shake
patient abl take botox cgrp
think probabl import question doctor current use
combin botox cgrp patient aimovig access program
doctor know trust botox migrain enthusiast take patient
product work even suffici
aimovig cgrp use botox think would major tailwind
cgrp market
step-edit
doc prescrib aimovig botox-experienc patient oner
approv process impact uptake/access
even competit cgrp think build first mover advantag
new competitor horizon
believ might potenti advantag bind receptor
rather ligand
long-term assum market share
exhibit competitor cgrp spacedrugdeveloperstatusbind cgrpdeliveryaimovigamgenon marketreceptorsubq monthlygalcanezumablillysept pdufaligandsubq monthlyfremanezumabtevaapprov mid septligandsubq monthli everi submiss plannedligandiv everi weekssourc cantor fitzgerald research compani data septemb
big piec pipelin biosimilar busi
view biosimilar busi meaning part busi
dont think investor give biosimilar busi credit brand
long-term guidanc biosimilar busi
exhibit biosimilar sale amgen product- cantor estimatessourc cantor biosimilar humira mvasi biosimilar avastin abp biosimilar remicad abp biosimilar rituxan kanjinti biosimilar herceptin biosimilar franchis could add alon top-lin
launch amjevita ex-u region
abbvi humira sale ex-u region launch biosimilar year
dig deeper pipelin
hematolog oncolog take bite bite
neurosci know
inflamm expans tezepelumab
broad pipelin investor view mani asset show-m stori
could see upsid pipelin readout next month
think could good set surpris pipelin broadli surpris
bace beta-secretas tslp thymic stromal lymphopoietin pituitari adenyl cyclas ico ligand induc costimulator-ligand cluster differenti bcma b-cell matur antigen
exhibit amgen novel therapeut pipelinetherapi developmenttargetfranchiseindicationphas baceneurologyalzheim atop myosincardiovascularchron heart ico bcma egfrviiihematology/oncologyvari half-lif extend bcma dllhematology/oncologyvari earlier muteininflamationlupu ra soc proteasom cantor fitzgerald research compani data septemb
mani product pipelin pay attent next month
speak amgen head global develop
legaci growth frontier growth framework think product
expect restudi tezepelumab atop dermat near futur
bite bispecif t-cell engag may import data late year help
understand drug match cell therapi approach
exhibit frontier growth asset productfranchisediseasephaseestim sale unadjust cantor data look encourag curiou els tslap usedmultipl hle biteshematolog oncologymultipl myeloma lymphoma think bispecif place io landscap think short half-lif prohibit first gener bitesamg come toward end year almost patient look asset differenti erenumabamg mutein lupu inflammatori preclin work interest focus happen clinic note nektar nr /lilli ow asset compani data cantor fitzgerald research septemb
within pipelin oncolog neurolog remain biggest point upsid
think street investor give littl credit
model close new pipelin revenu base case
unadjust pipelin contribut
think consensu give significantli less credit biosimilar busi think
credit given amjevita
exhibit pipelin newli launch product sale model base asthma aimovig migrain amjevita humira biosimilar mvasi avastin biosimilar abp remicad biosimilar abp rituxan biosimilar kanjinti herceptin biosimilar septemb
mani earli stage asset oncolog vari modal
think oncolog pipelin remain earli compar peer next month
give us answer
think compani make heavi invest io along mani
larg cap biotech peer like celg
flexibl around deliveri sinc bite car-t small molecul bispecif
gener littl credit given indic platform expans beyond imlyg
exhibit oncolog therapeut modalitiesmodalityproductstagesmal moleculeskyproli oprozomibapprov protiensaranespapprov antibodieskanjinti develop stage biosimilar bite antibodi constructsblincyto late earli clinicaloncolyt immunotherapi virusesimlygicapprov late earli clinicalcar-tsdevelop mention think kite md anderson collabor bite cartsbispecif antibodiesxencor collabor bispecif fc domain hle tcrscytomx probodi ind submit decemb compani report septemb
bite technolog bi-specif approach shown efficaci oncolog
acquir micromet
bite bi-specif cell engag connect cytotox lymphocyt cancer cell held
togeth flexibl linker
one domain target antigen surfac cancer cell
domain engag surfac cell
bite antibodi redirect t-cell target cell caus target-specif serial cell lysi
canon bite short half-lif make prone kidney
mediat clearanc half-lif hour continu dose need
exhibit bite mechan actionsourc amgen expect get clinic data bite platform earli decemb amgen seem
excit share
current bite platform short-act formul requir continu dose
data present leukemia multipl myeloma short-act bite
speak manag seem quit excit present new data updat
data expect near-term extend half-lif bite curiou see efficaci
bi-specif technolog show hematology-oncolog indic
exhibit bite approv pipelin program drugtargetbit formulationindicationphaseexpect bite continu acut lymphoblast leukemia marketwa approv dec acceler bite bite bite continu multipl bite extend bite extend bite weekli multipl extend bite weekli small cell lung extend bite weekli lymphomanot enrol patient yetsourc cantor fitzgerald research septemb
expand half-lif bite greater conveni
would expect efficaci profil fairli similar first-gener bite
hle bite data present primat late lorenczewski blood
new hle new target tandem single-chain fv antibodi fuse fc domain
fusion fc domain led hour half-lif singl dose primat
believ hard compar data car-t bite due differ trial
compar dataset philadelphia neg cell
view data respons rate strike data compar
make apples-to-orang blincyto compar vs chemotherapi kymriah
studi patient bridg chemotherapi get kymriah
also point car-t studi respons rate base evalu patient vs intent-
exhibit bite cart profilesbit bispecif cell engag antibodiescar-ttechnologymodifi bi-specif antibodymodifi autolog t-cellsautolog allogenicallogenicautologousadministrationcontinuouson time infusionefficacybest cr blincyto best cr releas syndrom neurotoxicitysimilarus solid tumorshasn shown bite feasibl antibodi technologyuncertain much research space around deliverymanufacturingfairli straightfowardcomplex/ take time/high cogstimingadminist demand week time manufacturingactiv therapaycan turn dosingcontinu infusionsourc cantor fitzgerald research companay data vs bite porter septemb
car-t vs bite two mechan similar modal clearli differ
outlin broad modal logist differ trial requir nuanc look
seen impress respons rate car-t think investor
clinician awar safeti concern
note clean comparison
exhibit -t vs bite bispecif t-cell engag bite bispecif cell engag antibodiestoverviewrecombin protein design bispecif cell engagerst cell redirect involv genet modif chimer antigen receptor technologymodifi bi-specif antibodi conscurr one lack fc regionus sampl patient cell engin sprout special structur call chimer antigen receptor surfac new receptor help cell identifi cancer bodyadministrationcould continu intervalon timeautolog allogenicallogenicautologousus solid tumorshasn shown bite feasibl antibodi technologyuncertain much research space around deliverymanufacturingfairli straightforwardcomplex/ take time/high cogsactiv therapycan turn offcontinuoustoxicitycytokin neurosimilarsourc compani data cantor fitzgerald septemb
interest point speak head clinic bite platform
caught dr elliott levi amgen svp head global develop
compani believ car-t efficaci
excit show data leukemia multipl myeloma show high activ
extend half-lif bite design efficaci regular bite
believ data shown bite becom clear
activ car-t
would good data bcma think key comparison
expect focu bcma excit target
expect mani compar data think care taken
differ two therapi studi
exhibit potenti bcma et al criteriar/r mm line therapi includ pi imid doubl refractori bothor r/r pi imid dara refractori last line therapymeasur diseaseecog mm regimen includ pi imidmeasur diseaseecog cell think similar dose cycl blincyto week week likelyrespons activ cr rate activ month activ month patient mrd-we could see unknown number patient month cantor fitzgerald research raje et al clinicaltri gov septemb
assum sale base case oncolog expans
think next month may give investor greater visibl think
assum roughli peak adjust sale pipelin oncolog platform sale
current blincyto imylg consensu sale
although hard know exactli indic bite modal lead charg
think make progress oncolog lead bigger commerci busi
ultim think place bite car-t patient cycl therapi
indic
migrain target antibodi could data later year
expect data later year full data present
larg fairli robust phase studi placebo control underway
studi first time target test
look
whether target work migrain though scientif literatur suggest play
potenti clinic differenti erenumab aimovig
potenti implic could expans migrain franchis differ
current model base case revenu
anoth target novarti relationship
pituitari adenyl cyclase-activ polypeptid pacap sensori trigemin neuron
vasodil found trigemin sensori parasympathet perivascular nerv fiber
select activ receptor
three pacap receptor pacap select
exhibit pac target methedologiessourc sourc rubio-beltran et al journal headach pain key basi studi target infus induc headach
migraine-lik attack small studi
anoth target novarti relationship
studi brain show healthi migrain patient infus
caus mild moder headach healthi migrain patient
migrain patient report migraine-lik attack hour start
peak median headach score lower drug use induc migrain
triptan use studi other well
exhibit evid migrainesourc winther schytz et al brain key basi studi target infus induc headach
migraine-lik attack small studi
anoth target novarti relationship
half-lif birk et al min paper conclud could
act initi cascad
possibl mechan induct headach migraine-lik attack list
peripher sensit trigemin sensori neuron
mast cell degranul secondarili lead activ peripher sensori trigemin fiber
facilit pain sensit central second-ord trigemin neuron
underway help us understand valid target
expect data later year full data present
erenumab reduc migrain day day vs day per month placebo
exhibit phase design antibodi migrain populationmigrain preventiondesigndoubl blind placebo controldoseslow highsampl treatment everi weeksprimari endpointchang baselin period monthli migrain day last week week doubl blind treatment periodsecondari endpoint achiev reduct baselin monthli migrain day chang baselin measur medic physic impair activ domain scoresinclusionmigrain frequenc day per month average across mo screen fail least medicationexclusionsmigrain continu pain patient older age migrain onsetestim primari complet dateoct ct gov clinicaltri gov would look opportun addit migrain franchis sinc could work
key take talk svp clinic develop elliott levi develop
work differ neuron cgrp
initi determin whether valid target migrain
nonclin toxic data clean seen safeti signal anim target
wide express vascular tissu
combin could long-term potenti
next question whether two target cgrp could differ activ
base scienc
speak think two medic could treat differ type migrain
receptor cgrp differ neuron
cgrp express trigemin sensori neuron autonom nervou system henc cgrp
inhibitor prevent express receptor could trigger migrain
express sphenopalatin ganglion parasympathet nervou system
target could potenti treat prevent migrain differ sourc
compar cgrp
outlin cgrp mechan
neuropeptid express trigemin system
associ mast cell degranul
infus cgrp lead headach immedi delay delay migrain lassen et al
cgrp level peripher central elev sever migrain attack
tezepelumab anti-tslp could implic mani allerg diseas
astrazeneca cover collabor get mid-singl digit royalti
profit split
tezepelumab anti-tslp antibodi bind human tslp stop interact
prevent releas proinflammatori cytokin immun cell target tslp
tslp cytokin express upstream lead releas cytokin like
exhibit tezepelumab mechan relev pathwayssourc natur review immunolog peterson et al result atop dermat didnt show robust efficaci may
reason
think still chanc tezepelumab ad
atop studi updat ct gov didnt show robust differ vs placebo
think manag still believ mechan action like work ad
exhibit /azn data tezepelumab atop dermatitisphas compar populationmoder sever atop dermatitisdesignplacebo controlsampl treatmentinject everi week dateaug juli cream weeksprimari endpointpati achiev endpoint decreas easi decreas easi scorediscontinu due medic activ vs controldiscontinu due seriou safeti activ vs placebolink result medimmun patient trial result summari astrazeneca like anoth atop dermat studi import
dont know compani plan start anoth studi
ask manag suggest import differ design
may led inconclus result
exhibit reason mention around atop dermat inconclus result tezepelumabstudi durationstudi week last dose week vs dupix studi exampl week would expect would studi anoth month longerstudi dose note data hand may suggest dose need higher explor dose use everi two week subqatop derm patient sever note popul milder diseas dupix studi may lower abil drug show treatment effect almost placebo patient achiev endpointus topic steroidspati treat steroid cream week up-front liber use made studi downregul signal key pathwaysourc cantor fitzgerald research septemb
what next tezepelumab
dont know compani plan start anoth studi
food allergi chop studi found tslp gene associ higher level children
estim peak sale asthma
model book revenu tezepelumab rest azn
asthma develop space remain crowd unmet need high
result consist think tezepelumab would uniqu posit
work low high eosinophil
think could potenti one compani bigger launch earli
exhibit tezepelumab asthma cantor estimatessourc cantor sales- ustezepelumab sales- ex-u septemb
interest mutein
mutat form fusion protein longer half-lif could expand regulatori
speak manag excit well
evid pretti strong inflammatori diseas sinc proleukin use mani diseas
current studi underway
rheumatoid arthriti probabl exploratori less clinic data
player space target t-reg expans via
three clinic program underway mutein
exhibit mutein trialslupu erythematosusrheumatoid arthriti ra chronic graft versu host diseas populationlupu erythematosusracgvhddesigndouble-blind placebo-controlleddouble-blind placebo-controlledopen labeldosesweekli bi-weekli dose tbdweekli bi-weekli dose tbdsampl endpointsafeti system lupu erythematosu respond index cutan lupu erythematosu diseas area sever index score clasi acr week dlt safetyph cgvhd nih consensu criteriasecondari endpointpk/pd sledai pk/pdsafeti failur free surviv symptom burden chang qolsourc cantor fitzgerald research clinicaltri gov product summari
amgen revenu young cantor sale biosimilar bergamo mn pharma imlyg corland aimovig sale base adjust sale total product amgen incom statement annual
revenu ex-aimovig sale product develop total gener administr total oper expens incom expens incom net exclud interest expens net incom expens net incom tax benefit incom tax tax incom ep ep amgen incom statement quarterli
amgen incom statementalethia young cantor fitzgeraldtot revenu dilut revenu ex-aimovig sale product research develop total gener administr total oper expens incom expens incom net exclud interest expens net incom expens net incom tax benefit incom tax tax incom ep ep ep ep amgen balanc sheet
balanc young cantor cash receiv current current plant equip asset portion long-term current defer tax tax non-current liabil exclud long-term tax equitypref stock addit paid-in comprehens loss stockhold liabil stockhold
statementalethia young cantor compens incom item net exclud defer incom oper asset liabil net acquisitionstrad receiv incom tax liabil exclud long-term tax cash provid oper market sale market matur market paid acquisit net cash properti plant restrict invest intang sale properti plant exclud proce sale properti plant cash use provid invest proce issuanc common proce issuanc common stock connect compani equiti award programssettl conting consider exclud settlement conting consider tax aris share withheld share-bas cash use provid financ manag profil
robert bradway chairman ceo robert bradway chairman chief execut offic bradway becam
chairman januari chief execut offic may bradway serv compani presid chief oper
offic may may appoint amgen board director octob join compani
vice presid oper strategi serv execut vice presid chief financi offic april
david melin evp cfo david melin join execut vice presid chief financi offic melin
respons financ inform system global busi servic investor relat prior melin
senior vice presid chief financi offic join melin serv variou
capac includ vice presid chief financi offic gm north america
elliott levi develop elliott levi senior vice presid global develop respons
clinic develop pipelin join levi serv senior vice presid head specialti
develop bristol-my squibb bm prior role held posit senior vice presid global
pharmacovigil epidemiolog
diversifi biopharmaceut compani special six therapeut area includ cardiovascular diseas oncolog
bone health neurosci nephrolog inflamm compani also grow biosimilar franchis
